Novartis' Narasimhan Bullish On Cosentyx Keeping Market Lead
This article was originally published in Scrip
Novartis AG hopes new Phase III data showing most patients were able to maintain clear or nearly clear skin for up to three years by using Cosentyx (secukinumab) will reinforce and expand use of its new plaque psoriasis treatment.
You may also be interested in...
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.